Skip to main content
    I

    Immix Biopharma Inc (IMMX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.68
    +0.17 (+2.00%)

    Market Cap: $720.43M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    44%(7/16)
    Avg Surprise
    -13.56%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.19
    Range$-0.21 - $-0.17
    7 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.17-9.8%
    60d ago$-0.18-7.3%
    30d ago$-0.19+1.6%
    7d ago$-0.190.0%
    Current$-0.19
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.14
    Range$-0.20 - $0.06
    8 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.14---
    Sep 26EST
    		-$-0.19---
    Jun 26
    Reported Aug 7
    		$-0.18$-0.17-5.88%Miss+18.2%
    Mar 26
    Reported May 7
    		$-0.18$-0.21+14.29%Beat-20.0%
    Dec 25
    Reported Mar 25
    		$-0.28$-0.15-86.67%Miss-12.0%
    Sep 25
    Reported Nov 7
    		$-0.24$-0.19-26.32%Miss+0.0%
    Jun 25
    Reported Aug 8
    		$-0.22$-0.16-37.50%Miss-46.7%
    Mar 25
    Reported May 8
    		$-0.15$-0.23+34.78%Beat+31.8%
    Dec 24
    Reported Mar 24
    		$-0.25$-0.25+0.00%Beat-8.7%
    Sep 24
    Reported Nov 12
    		$-0.24$-0.16-50.00%Miss-4.3%
    Jun 24
    Reported Aug 12
    		$-0.15$-0.21+28.57%Beat+37.5%
    Mar 24
    Reported May 9
    		$-0.22$-0.23+4.35%Beat-22.2%
    Dec 23
    Reported Mar 29
    		$-0.23$-0.23+0.00%Beat+14.8%
    Sep 23
    Reported Nov 9
    		$-0.23$-0.23+0.00%Beat-108.7%
    Jun 23
    Reported Aug 11
    		$-0.24$-0.17-41.18%Miss-118.2%
    Mar 23
    Reported May 12
    		$-0.18$-0.14-28.57%Miss-80.0%
    Dec 22
    Reported Mar 27
    		$-0.27$-0.22-22.73%Miss+91.5%
    Sep 22
    Reported Nov 9
    		$-0.11$-0.11-0.18%Miss-451.0%
    Jun 22
    Reported Aug 12
    		$-0.11N/AN/ABeat+31.3%
    Mar 22
    Reported May 13
    		$-0.10N/AN/ABeat+44.9%
    Dec 21
    Reported Mar 28
    		$-3.16N/AN/ABeat-1641.0%
    Sep 21
    Reported Dec 17
    		$-0.02$0.00N/AMiss+42.0%
    Jun 21
    Reported Sep 17
    		$-0.16$0.00N/AMiss-306.1%
    Mar 21
    Reported Jun 29
    		$-0.18$0.00N/AMiss-360.7%
    Dec 20
    Reported Mar 31
    		$-0.18$0.00N/AMiss-
    Jun 20
    Reported Sep 30
    		$-0.03$0.00N/AMiss-
    Mar 20
    Reported Jun 29
    		$-0.04$0.00N/AMiss-
    Dec 19
    Reported Mar 30
    		$-0.04$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-9.86EV/EBITDAN/A
    Price/FCF-14.16xFCF Yield-7.06%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-34.20%ROIC-18.20%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio25.13xQuick Ratio25.13x
    Trading Statistics
    Beta0.24Avg Volume1.75M
    52-Week High$15.1052-Week Low$2.67

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$9.28
    SMA 20$10.39
    SMA 50$11.70
    SMA 200$9.31
    EMA 10$9.33
    EMA 20$10.11
    EMA 50$10.83
    EMA 200$9.19

    MACD

    Line: -0.90Signal: -0.74Hist: -0.17

    ADX

    ADX: 39.4+DI: 7.9-DI: 28.8

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down96.0
    PSAR$9.42

    Bollinger Bands

    Upper Band$13.11
    Lower Band$7.68
    %B Position5224%(Upper)
    Band Width0.18

    RSI (14-Day)

    Neutral
    30.3

    Momentum Oscillators

    Stoch %K3.7
    Stoch %D4.8
    Williams %R-92.4
    ROC (10d)-15.2%
    Momentum-1.55
    CCI (20d)-102.2
    MFI (14d)19.5

    Volatility Measures

    ATR (14d)$0.69(8.0%)
    StdDev (20d)1.36
    Hist Vol59.0%(High)

    Volume Flow

    VWAP$8.69
    OBV18.2M
    AD Line1.5M
    CMF (20d)-0.273

    Volume Metrics

    Avg Vol (20d)1.8M
    Vol Ratio0.7x
    VWMA (20d)$10.54

    Pivot Points

    R3$9.23
    R2$9.05
    R1$8.78
    Pivot Point$8.60
    S1$8.33
    S2$8.15
    S3$7.88

    Advanced Oscillators

    TSI-34.14
    Ultimate Osc36.7
    KST-246.70

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$96,290$0$0$0$4,784$0
    Cost of Revenue$0$0$90,631$0$0$0N/A$0$0$0$3,076$0
    Gross Profit$0$0$-90,631$0$0$0$48,145$0$0$0$1,708$0
    Operating Expenses$12.46M$10.80M$10.89M$7.66M$6.72M$4.68M$4.99M$7.39M$4.70M$5.59M$5.38M$4.52M
    R&D$5.33M$5.98M$5.73M$4.58M$3.97M$1.98M$1.37M$4.45M$2.22M$3.25M$3.10M$2.11M
    SG&A$7.12M$4.82M$5.17M$3.08M$2.75M$2.71M$3.61M$2.95M$2.48M$2.34M$2.28M$2.42M
    Operating Income$-12,456,343$-10,803,855$-10,893,276$-7,662,509$-6,717,705$-4,682,925$-4,987,120$-7,394,931$-4,702,496$-5,590,133$-5,375,852$-4,523,796
    Interest Income$913,663$717,168$216,712$84,539$104,056$150,219$185,851$256,680$306,915$267,908$228,575$186,691
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-11,542,680$-10,086,687$-10,676,564$-7,577,970$-6,613,649$-4,532,706$-4,801,269$-7,138,251$-4,395,581$-5,322,225$-5,147,277$-4,337,105
    Income Tax Expense$14,322$0$11,266$7,722$8,914$9,822$10,785$11,144$10,269$8,839$8,089$6,807
    Net Income$-11,557,002$-10,086,687$-10,687,830$-7,585,692$-6,622,563$-4,542,528$-4,812,054$-7,149,395$-4,405,850$-5,331,064$-5,155,366$-4,343,912
    EBITDA$-12,325,459$-10,673,089$-10,802,645$-7,527,654$-6,637,870$-4,623,745$-4,945,783$-7,369,025$-4,678,201$-5,566,283$-5,372,776$-4,522,415
    EBIT$-12,456,343$-10,803,855$-10,893,276$-7,662,509$-6,717,705$-4,682,925$-4,987,120$-7,394,931$-4,702,496$-5,590,133$-5,375,852$-4,523,796
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IMMX

    News

    Immix Biopharma, Inc. (IMMX) Stock Price, News, Quote & History

    Immix Biopharma, Inc. (IMMX) is a clinical-stage biopharmaceutical company focused on developing chimeric antigen receptor cell therapy for light chain Amyloidosis and immune-mediated diseases. The company's stock shows...

    Yahoo! Finance Canada•10/6/26•Bullish

    Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

    Immix Biopharma, a global leader in AL Amyloidosis, announced its participation in the 45th Annual J.P. Morgan Healthcare Conference, scheduled for January 11-14, 2027...

    GlobeNewswire•10/5/26•Bullish

    Immix Biopharma to Present at the 45th Annual J.P. Morgan Healthcare Conference

    Immix Biopharma (IMMX) will present at the 45th Annual J.P. Morgan Healthcare Conference from January 11-14, 2027, to showcase its advancements in treating AL Amyloidosis. The company is a leader in this severe disease...

    Quiver Quantitative•10/5/26•Bullish

    Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study

    Immix Biopharma reported updated clinical data for its investigational CAR T-cell therapy, NXC-201, for relapsed or refractory light-chain (AL) amyloidosis...

    TradingView•10/5/26•Bullish

    Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study

    Immix Biopharma announced updated clinical data for its NXC-201 CAR T-cell therapy for relapsed or refractory AL amyloidosis...

    Yahoo Finance•10/4/26•Bullish

    IMMX Valuation and Fair Value

    P/E
    -9.9x
    P/FCF
    -14.2x
    P/B
    2.4x
    See GNG's fair value

    IMMX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -18.2%
    ROE
    -34.2%
    FCF yield
    -7.1%

    IMMX Competitors

    CompanyTicker
    Enhabit Inc.EHAB
    Collegium Pharmaceutical IncCOLL
    Candel Therapeutics IncCADL
    Adlai Nortye Ltd. American Depositary SharesANL
    Geron CorporationGERN
    Verastem IncVSTM
    Varex Imaging CorpVREX
    Sana Biotechnology IncSANA

    Sector: Healthcare

    IMMX Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    3
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0

    IMMX Bull Case vs Bear Case

    Bull case

    • 100.0% of IMMX's analyst ratings are Buy or Strong Buy.

    Bear case

    • IMMX beat EPS estimates in 25.0% of its last 8 reported quarters.

    IMMX Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -19.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.19
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 2 down

    Frequently Asked Questions About IMMX

    Does IMMX pay dividends?

    Immix Biopharma Inc (IMMX) does not currently pay a regular dividend.

    What is IMMX's market cap?

    Immix Biopharma Inc (IMMX) has a market capitalization of $720.43M with a current stock price of $8.68.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In